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SCIENTIFIC EDITORIAL
Management of prosthetic heart valve obstruction:
Speech for the surgery?
Prise en charge des thromboses de prothèses valvulaires cardiaques :
plaidoyer pour la chirurgie ?
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Prosthetic valve thrombosis has a reported incidence of 0.1 to 5.7% per patient-year. Major
contributing factors are inadequate anticoagulant therapy and mitral location of the pros-
thesis. Valve thrombosis occurs with similar frequency in patients with bioprosthetic valves
and in those with mechanical valves who are receiving adequate anticoagulant therapy.
Likewise, in patients receiving adequate anticoagulation, the incidence of valve thrombosis
is similar with caged-ball, single tilting disk and bileaﬂet valves.
Prosthetic valve thrombosis is a potentially life-threatening condition that requires
prompt recognition and urgent treatment. The diagnosis may not be clinically apparent in
some patients because of either minimal symptoms or intermittency of valve dysfunction.
Typically, patients have acute haemodynamic deterioration requiring immediate medical
attention. Physical examination is frequently insufﬁcient, and diagnosis of valve throm-
bosis is established by ﬂuoroscopy, transthoracic echocardiography (TTE) and above all
transesophageal echocardiography (TEE).
The choice of optimal management remains controversial. Once the diagnosis of valve
thrombosis is established, intravenous heparin therapy should be initiated promptly. IfThrombolyse ;
Chirurgie ;
Échocardiographie
transœsophagienne
the thrombus is less than 5mm in diameter on echocardiography and is not obstruct-
ing the valve, the patient can be treated with anticoagulation alone. The presence of
a thrombus 5mm or more in diameter is usually associated with a complicated course,
requiring a more aggressive therapy such as ﬁbrinolysis or valve replacement. The mor-
tality rate associated with surgical therapy for valve obstruction is approximately 15%
 Management of prosthetic heart valve obstruction: Fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre
study of 263 cases, Roudaut R, Laﬁtte S, Roudaut M-F, Reant P, Pillois X, Durrieu-Jaïs C, Coste P, Deville C, Roques X, doi:10.1016/j.acvd.
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ut may be substantially higher for emergency operations in
atients with haemodynamic instability. Valve replacement
s preferred to thrombectomy because of the lower inci-
ence of recurrent thrombosis. Thrombolytic therapy has
success rate of 70% and a mortality rate of 9 to 11%; it is
ore efﬁcacious for aortic valve thrombosis than for mitral
alve thrombosis as well as for patients with symptoms of
ess than 2weeks’ duration. Since thrombolytic therapy car-
ies a considerable risk of embolization (up to 19%), it should
e reserved for critically ill patients whose operative risk is
igh.
The article by Roudaut et al. [1] in this issue of the
rchives of Cardiovascular Diseases conﬁrms that prompt
urgical treatment is associated with a better early success
ate and a signiﬁcantly lower incidence of complications
han ﬁbrinolysis in left-side prosthetic heart valve obstruc-
ion. The authors report on 263 cases in 210 patients, 127
f whom were treated by ﬁbrinolysis and 136 by surgery,
ver a 23-year period. There was no difference between
he two groups in the mortality rate: 10%. However, haemo-
ynamic success was more frequent in the surgical group
89%) versus the ﬁbrinolysis group (70.9%); embolic events
ere more frequent in the ﬁbrinolysis group (15% versus
.7%) as were total complications (25.2% versus 11.1%). Dur-
ng the 1980s, ﬁbrinolysis was used at ﬁrst. However, since
990, with the introduction of TEE, surgery is preferred,
erhaps because TEE has demonstrated incomplete haemo-
ynamic success with ﬁbrinolysis (greater sensitivity of TEE
or residual thrombus detection) together with a risk of
omplications: systemic or peripheral embolism, transient
schaemic attacks. . .and recurrences.
This is the largest, single-centre, retrospective but non-
andomized series reported in the literature. These results
re in agreement with those reported previously [2—4],
articularly the recent publication by the Montreal Heart
nstitute [5]. The authors reported their 20-year experience:
430 operations, 4924 patients and 39 cases of prosthetic
alve thrombosis, and a surgical procedure rate of 82%
thrombectomy 47%, mitral valve replacement 47%, aortic
alve replacement 6%). The 30-day operative mortality was
5%, and the 10-year actuarial survival after prosthetic valve
hrombosis was 46%. However, in this study, valve thrombec-
omy was performed in patients with fresh thrombi related
o a recent change in the anticoagulation management,
nd valve replacement was performed in all other patients.
oreover, before discharge, aspirin was added to warfarin
reatment. . .
In contrast, for intravenous thrombolytic treatment of
echanical prosthetic valves, a study using serial TEE over
4-year period in 32 symptomatic patients relates an initial
uccess of 53%, increasing to 88% after repeated throm-
olytic sessions, with rates of 2% for death and 2.8%
or cerebral embolization [6]. For these authors, intra-
enous thrombolysis was associated with a low risk of
omplications and a high rate of success in both obstructive
nd non-obstructive prosthetic valve thrombosis. Similarly,
or Shapira et al. [7], in a series of 12 patients with stuck
ileaﬂet mitral valves without large clots (< 5mm), throm-
olysis offered a valid alternative to surgery, with a high
uccess rate (83.9%) and minimal complications (33.3%). In
hese studies, the success rate for ﬁbrinolysis was higher
han in Roudaut et al.’s study (88 and 83.9% versus 70.9%),P. Maribas
lthough the populations are different. Therefore, two
emarks are important and can explain the reverse in
trategy during the past two decades (decreasing use of
brinolysis and increasing use of surgery).
Firstly, TEE ﬁndings are very important in guiding ther-
py, showing thrombus size and location [8], with a risk
f complications: systemic or peripheral embolism or tran-
ient ischaemic attacks. . .and recurrences with ﬁbrinolysis.
n addition, TEE can reveal pannus formation, deﬁned as
xcessive wound ﬁbrosis around a prosthetic valve, and is a
eﬁnite indication for prosthetic valve replacement.
Secondly, over the past 20 years, recent advances in sur-
ical technique (shorter extracorporeal circulation and cross
lamp time, better protection, fast track, etc.) as well as
n intensive care unit management, have improved surgical
esults.
In conclusion, in agreement with guidelines from the
uropean Society of Cardiology [9], surgery is recommended
or obstructive valve thrombosis except for:
critically ill patients (with comorbid conditions severely
impaired cardiac function prior to developing valve
thrombosis);
when surgery is not available immediately and for non-
transferable patients;
thrombosis of tricuspid or pulmonary valves, in which
case, ﬁbrinolysis should be considered.
For non-obstructive prosthetic thrombosis, management
epends on the existence of thromboembolic events and on
hrombus size: medical therapy (optimized anticoagulation)
or a small thrombus (< 10mm) and surgery for large ones
≥ 10mm) or for thrombus complicated by embolism.
Aspirin can be added to anticoagulant treatment [10].
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